A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Proceedings of the National Academy of Sciences · 09.06.2026 · 123 (23)
DOI: 10.1073/pnas.2610708123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 01.06.2026. Verfasst von Vasiliki Liaki und 23 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Group, Tumor Biology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CRIS Cancer Foundation (CRIS Foundation), EC | European Research Council (ERC), MEC | Agencia Estatal de Investigación (AEI).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the door to more efficacious therapies although their beneficial effect is still limited mainly due to the rapid appearance of tumor resistance. Here, we demonstrate that genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) KRAS signaling pathways leads to complete and permanent regression of orthotopic PDACs induced by K ras / T p53 mutations. Likewise, a combination of selective inhibitors of KRAS (RMC-6236/daraxonrasib), EGFR family (afatinib), and STAT3 (SD36) induced the complete regression of orthotopic PDAC tumors with no evidence of tumor resistance for over 200 d posttreatment. This combination therapy also led to significant regression of genetically engineered mouse tumors as well as patient-derived tumor xenografts (PDX) in the absence of tumor relapses. Of importance, this combination therapy was well tolerated. In sum, these results should guide the development of new clinical trials that may benefit PDAC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Oncology Group, Tumor Biology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
- Centro de Investigación Biomédica en Red Cancer, Madrid 28029, Spain.
- Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas - Universidad de Salamanca, Salamanca…
- Cancer Stem Cells and Fibroinflammatory Microenvironment Group, Instituto de Investigaciones Biomédicas Sols-Morreale, Consejo Superior de Investigaciones Científicas - Universidad Autónoma de Madrid, Madrid 28029, Spai…
- Biomarkers and Personalized Approach to Cancer Group, Area 3 Cáncer, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid 28049, Spain.
- Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad Complutense, Madrid 28040, Spain.
ORCID-Profile: Ruth Álvarez, Matthias Drosten, Bruno Sainz, Monica Musteanu, Eduardo Caleiras, Nelson Dusetti, Valeria Poli, Carmen Guerra, Mariano Barbacid
Förderung
- CRIS Cancer Foundation (CRIS Foundation)
- EC | European Research Council (ERC)
- MEC | Agencia Estatal de Investigación (AEI)
- EC | European Regional Development Fund (ERDF)
- EC | NextGenerationEU (NGEU)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)
- MEC | Instituto de Salud Carlos III (ISCIII)
- Asociación Cáncer de Páncreas (ACANPAN)
Zitieren
APA
Liaki, V., Barrambana, S., Kostopoulou, M., Lechuga, C. G., Zamorano-Dominguez, E., Acosta-Gallego, D., Morales-Cacho, L., Álvarez, R., Sun, P., Rosas-Perez, B., Barrero, R., Jiménez-Parrado, S., López-García, A., San Roman, M., López-Gil, J. C., Drosten, M., Sainz, B., Musteanu, M., Caleiras, E., …, & Barbacid, M. (2026). A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences, 123(23). https://doi.org/10.1073/pnas.2610708123
Vancouver
Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta-Gallego D, et al. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Proceedings of the National Academy of Sciences. 2026;123(23). doi:10.1073/pnas.2610708123
BibTeX
@article{Liaki2026,
author = {Liaki, Vasiliki and Barrambana, Sara and Kostopoulou, Myrto and Lechuga, Carmen G and Zamorano-Dominguez, Elena and Acosta-Gallego, Domingo and Morales-Cacho, Lucía and Álvarez, Ruth and Sun, Pian and Rosas-Perez, Blanca and Barrero, Rebeca and Jiménez-Parrado, Silvia and López-García, Alejandra and San Roman, Marta and López-Gil, Juan Carlos and Drosten, Matthias and Sainz, Bruno and Musteanu, Monica and Caleiras, Eduardo and Dusetti, Nelson and Poli, Valeria and Sánchez-Bueno, Francisco and Guerra, Carmen and Barbacid, Mariano},
title = {A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {23},
doi = {10.1073/pnas.2610708123}
}
EUVIMED